In May 2021, pegcetacoplan was approved by the US FDA to treat adults with paroxysmal nocturnal hemoglobinuria (PNH), and it is the first to target C3, a complement component upstream of C5 [40]. The gene discussed is C3; the disease is paroxysmal nocturnal hemoglobinuria.